An investment perspective by Portfolio Manager Chris Yoo

Wonderlab Bio: Harnessing the Power of Cell Differentiation for Research and Medicine

Our fund recently wrote a check to kick off the Series A raise for Wonderlab Bio and I couldn’t be more excited. 

We have been tracking the development of inducible pluripotent stem cells (iPSCs) as a platform for new ways to study and treat diseases that accompany aging. And now, after several years of getting to know Robin Smith, the founder and CEO, and his new company, Wonderlab Bio, we strongly believe that his approach and the proprietary assets he has built present a great opportunity for us to invest at the earliest stage.

When we invest, we look for certain key characteristics in opportunities. One major attribute that stands out for Wonderlab Bio is the asset. We are constantly searching for technologies that are hard to build, expensive to replicate, and able to create value across several end markets at once. Wonderlab Bio has built just that kind of asset. 

The company has assembled what we believe is the largest HLA-matched allogeneic iPSC cell bank in the world, and it is now commercializing across multiple revenue streams. This is exactly the profile we want exposure to: an infrastructure-grade moat with multiple, independent paths to value.

“Blood bank for stem cells”

Wonderlab Bio has built the stem-cell equivalent of a pre-typed blood bank for the American population. From more than 85,000 commercially consented blood samples, the company has identified more than 65 rare “super donor” lines that, because of their genetics, are immune-compatible with over 90% of the US population. This means that use of these cells in research models by biopharmaceutical companies developing cell therapies can be most easily and quickly translated into therapeutics with the widest potential application. And because the cells are pluripotent, new model systems and direct application to any disease setting are directly possible. The Wonderlab bio bank produces many cell types including cartilage cells, heart cells, neurons, and immune cells, and they are just at the beginning. 

Additional key characteristics we look for are an unfair competitive advantage and strong intellectual property position. Our conviction here is based on Wonderlab Bio’s fundamental structural advantage. The bank took over a decade and more than $57 million to assemble, and it sits behind a comprehensive patent estate. We know from market research studies that the iPSC market has been projected to grow at approximately 10% per year and is roughly a $2 billion market size just for pharmaceutical drug discovery. However, when considered against the conservatively estimated $150 billion of biopharma R&D expenditures alone, we believe investing in a strong mover like Wonderlab Bio is planning for the transformation that is underway in the adoption and widespread use of more biologically faithful cell models.

This also points to the equally massive and exciting therapeutic opportunities that regenerative medicine and stem cell markets represent as the future of medicine today, currently at approximately $17 billion with a 21% CAGR. The FDA’s push toward non-animal models, the structural shift from autologous to off-the-shelf allogeneic therapies, and an aging population all point demand toward standardized, population-matched cell supply. For context, Japan’s government-funded CiRA initiative spent on the order of $275 million to produce three super donor lines covering about 30% of a single country. Wonderlab Bio covers more than 90% of a far more genetically diverse population, at six or more HLA loci, with full commercial consent and in vivo therapeutic validation. Wonderlab Bio has a running fast start compared to all other commercially available cell banks.

A founder who perseveres

I met Robin four years ago but our paths have crossed several times over the past twenty-five years. Robin invented one of the first electronic laboratory notebooks back when submissions of data to the FDA about therapeutics by pharmaceutical companies used to be delivered literally “by the truckload”, and has now become indispensably electronic. (By the way, see one of our other recent investments, Hill Research for the story of why that one transformation has now led to the application of AI to cut months and years from approval timelines). Founder and CEO Robin Smith is the quintessential life sciences serial entrepreneur.He has four prior exits23 granted and pending patentsand the experience of managing R&D groups with large budgets inside companies like Perkin Elmer.  

As a small example of his tenacity, when the cell bank was at risk of being discontinued by a private equity group, Robin negotiated the acquisition of the assets under commercially favorable terms so that he could accelerate the commercialization in an even more efficient path through Wonderlab Bio.

The business model is deliberately de-risked across three components of the platform running off one cost base. This is the key insight that Robin developed as he sought to reformulate the commercialization plan for the cell bank assets.  

Wonderlab Bio’s recurring revenue is starting in the biopharmaceutical research tools market with the first product as a premium optogenetic (“all-optical”) cardiomyocyte cell line for artifact-free cardiac-safety screening. The importance of this product cannot be overstated. 

Immediate improvement for drug development

Drug induced cardiotoxicity remains a leading cause of late stage failures and post market withdrawals, yet the legacy assays the industry still relies on are imprecise. They flag too many viable compounds as dangerous while still missing real risk, which means some promising drugs often get killed while other unsafe ones may still advance. 

Wonderlab’s optogenetic cardiomyocyte line attacks this problem. Because the cells are paced and read entirely with light, the assay removes the electrical artifacts, rate variability, and low throughput that limited every prior approach, producing a cleaner, more predictive readout on human, population-representative cells. This is precisely the direction regulators have been steering the field toward through the FDA’s CiPA initiative and the broader move away from animal models. 

Just as important from where we sit as investors, this is a research tool and not a therapeutic, so it generates high-margin recurring revenue today with no clinical approval required, and it places Wonderlab inside the daily workflow of the same biopharma customers who become partners for the rest of the catalog and the therapeutics pipeline.

Additional cell lines that are strategic lynchpins for biopharma drug development are right behind the optogenetic cardiomyocyte cell line. Additional revenue will be layered in from the successful winning of competitive non-dilutive federal funding that underwrites operations and manufacturing scale-up at zero equity dilution. Wonderlab Bio has already participated as an ARPA-H project team member supplying the critical cell lines for a lead cartilage program. 

Longer term, Wonderlab Bio is developing a therapeutics pipeline, led by an injectable, off-the-shelf cartilage-repair candidate for knee osteoarthritis, a market with 32.5 million US patients and no disease-modifying therapy today, with a first IND targeted for 2027.  Robin’s vision and leadership have been the key difference makers in this bold, new commercial strategy.

Wonderlab is currently raising its Series A to convert the platform from preclinical to clinical-stage and to scale the tools business. We would welcome you alongside us. If you would like access to the data room and the detailed model, we are glad to arrange it.